Search

Your search keyword '"Eisterer, Wolfgang"' showing total 277 results
Start Over Author "Eisterer, Wolfgang"
277 results on '"Eisterer, Wolfgang"'

5. Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial

Author

Dong, Yawen, primary, Santol, Jonas, additional, Gruenberger, Birgit, additional, Lenauer, Alfred, additional, Laengle, Friedrich, additional, Thaler, Josef, additional, Piringer, Gudrun, additional, Eisterer, Wolfgang, additional, Djanani, Angela, additional, Stift, Judith, additional, and Gruenberger, Thomas, additional

Published
2024
Full Text
View/download PDF

6. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)

Author

Kasper, Bernd, primary, Pink, Daniel, additional, Rothermundt, Christian, additional, Richter, Stephan, additional, Augustin, Marinela, additional, Kollar, Attila, additional, Kunitz, Annegret, additional, Eisterer, Wolfgang, additional, Gaidzik, Verena, additional, Brodowicz, Thomas, additional, Egerer, Gerlinde, additional, Reichardt, Peter, additional, Hohenberger, Peter, additional, and Schuler, Markus K., additional

Published
2024
Full Text
View/download PDF

9. Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma – an Austrian expert consensus statement

Author

Taghizadeh, Hossein, primary, Djanani, Angela, additional, Eisterer, Wolfgang, additional, Gerger, Armin, additional, Gruenberger, Birgit, additional, Gruenberger, Thomas, additional, Rumpold, Holger, additional, Weiss, Lukas, additional, Winder, Thomas, additional, Wöll, Ewald, additional, and Prager, Gerald W., additional

Published
2023
Full Text
View/download PDF

10. LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study

Author

Piringer, Gudrun, primary, Gruenberger, Thomas, additional, Thaler, Josef, additional, Kührer, Irene, additional, Kaczirek, Klaus, additional, Längle, Friedrich, additional, Viragos-Toth, Istvan, additional, Amann, Arno, additional, Eisterer, Wolfgang, additional, Függer, Reinhold, additional, Andel, Johannes, additional, Pichler, Angelika, additional, Stift, Judith, additional, Sölkner, Lidija, additional, Gnant, Michael, additional, and Öfner, Dietmar, additional

Published
2023
Full Text
View/download PDF

11. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

Author

Brodowicz, Thomas, Mir, Olivier, Wallet, Jennifer, Italiano, Antoine, Blay, Jean-Yves, Bertucci, François, Eisterer, Wolfgang, Chevreau, Christine, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Ryckewaert, Thomas, Liegl-Antzwager, Bernadette, Thery, Julien, Penel, Nicolas, Le Cesne, Axel, and Le Deley, Marie-Cécile

Published
2018
Full Text
View/download PDF

13. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

14. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Mir, Olivier, Brodowicz, Thomas, Italiano, Antoine, Wallet, Jennifer, Blay, Jean-Yves, Bertucci, François, Chevreau, Christine, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Salas, Sébastien, Perrin, Christophe, Delcambre, Corinne, Liegl-Atzwanger, Bernadette, Toulmonde, Maud, Dumont, Sarah, Ray-Coquard, Isabelle, Clisant, Stéphanie, Taieb, Sophie, Guillemet, Cécile, Rios, Maria, Collard, Olivier, Bozec, Laurence, Cupissol, Didier, Saada-Bouzid, Esma, Lemaignan, Christine, Eisterer, Wolfgang, Isambert, Nicolas, Chaigneau, Loïc, Cesne, Axel Le, and Penel, Nicolas

Published
2016
Full Text
View/download PDF

15. A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients

Author

Piringer, Gudrun, Fridrik, Michael, Fridrik, Alfred, Leiherer, Andreas, Zabernigg, August, Greil, Richard, Eisterer, Wolfgang, Tschmelitsch, Jörg, Lang, Alois, Frantal, Sophie, Burgstaller, Sonja, Gnant, Michael, Thaler, Josef, and on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Published
2018
Full Text
View/download PDF

19. Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Author

GERGER, ARMIN, primary, EISTERER, WOLFGANG, additional, FUXIUS, STEFAN, additional, BASTIAN, SARA, additional, KOEBERLE, DIETER, additional, WELSLAU, MANFRED, additional, SANOYAN, DILARA AKHOUNDOVA, additional, MAAS, CHRISTIAN, additional, UHLIG, JENS, additional, FENCHEL, KLAUS, additional, GREIL, RICHARD, additional, VON DER HEYDE, EYCK, additional, AGOCS, GAËLLE RHYNER, additional, WEIDE, RUDOLF, additional, SCHWAGER, MONIKA, additional, REICHENBACH, FRANK, additional, MODEST, DOMINIK PAUL, additional, and FRITSCH, RALPH, additional

Published
2022
Full Text
View/download PDF

26. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Lordick, Florian, Eisterer, Wolfgang, Hegewisch-Becker, Susanna, Thuss-Patience, Peter, Pritzkuleit, Ron, Schweizerische Gesellschaft Für Hämatologie, Schweizerische Gesellschaft Für Medizinische Onkologie, Arnold, Dirk, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Borner, Markus M., Wöll, Ewald, Bruns, Christiane, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Faber, Gerhard, Sinn, Marianne, Stahl, Michael, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, and Möhler, Markus

Subjects
Medizin und Gesundheit
Published
2021
Full Text
View/download PDF

27. Konsensus Diagnose und Therapie von Weichteilsarkomen

Author

Brodowicz, Thomas, Amann, Gabriele, Leithner, Andreas, Sztankay, Arpad, Kainberger, Franz, Eisterer, Wolfgang, Liegl-Atzwanger, Bernadette, Rachbauer, Franz, Rath, Thomas, Bergmann, Michael, Funovics, Philipp T., Ploner, Ferdinand, and Windhager, Reinhard

Published
2012
Full Text
View/download PDF

28. Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer: A Phase II Study

Author

Öfner, Dietmar, DeVries, Alexander F., Schaberl-Moser, Renate, Greil, Richard, Rabl, Hans, Tschmelitsch, Jörg, Zitt, Matthias, Kapp, Karin S., Fastner, Gerd, Keil, Felix, Eisterer, Wolfgang, Jäger, Robert, Offner, Felix, Gnant, Michael, Thaler, Josef, and TAKO 05/ABCSG R-02 Trial Investigators

Published
2011
Full Text
View/download PDF

29. First annual report of the Austrian CML registry

Author

Schmidt, Stefan, Wolf, Dominik, Thaler, Josef, Burgstaller, Sonja, Linkesch, Wolfgang, Petzer, Andreas, Fridrik, Michael, Lang, Alois, Agis, Hermine, Valent, Peter, Krieger, Otto, Walder, Alois, Korger, Markus, Schlögl, Ernst, Sliwa, Tamer, Wöll, Ernst, Mitterer, Manfred, Eisterer, Wolfgang, Pober, Michael, and Gastl, Günther

Published
2010
Full Text
View/download PDF

34. Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur

Author

Wörmann, Bernhard (Prof. Dr. med.), Bokemeyer, Carsten (Prof. Dr. med.), Burmeister, Thomas (PD Dr. Dr. med.), Köhne, Claus-Henning (Prof. Dr. med.), Schwab, Matthias (Prof. Dr. med.), Arnold, Dirk (Prof. Dr. med.), Blohmer, Jens-Uwe, Borner, Markus, Brucker, Sara (Dr. med.), Cascorbi, Ingolf (Prof. Dr. med. Dr. rer. nat.), Decker, Thomas (Prof. Dr. med.), Wit, Maike de, Dietz, Andreas (Prof. Dr. med.), Einsele, Hermann (Prof. Dr. med.), Eisterer, Wolfgang, Folprecht, Gunnar (PD Dr. med.), Hilbe, Wolfgang (Prim. Univ.-Prof. Dr.), Hoffmann, Jürgen (Prof. Dr. med. Dr. med. dent.), Knauf, Wolfgang (Dr. med.), Kunzmann, Volker (Prof. Dr. med.), Largiadèr, Carlo R., Lorenzen, Sylvie (Dr. med.), Lüftner, Diana (Prof. Dr. med.), Moehler, Markus (Prof. Dr. med.), Nöthen, Markus M. (Prof. Dr.), Pox, Christian P. (Prof. Dr. med.), Reinacher-Schick, Anke Claudia (Prof. Dr. med.), Scharl, Anton, Schlegelberger, Brigitte (Prof. Dr. med.), Seufferlein, Thomas (Prof. Dr. med.), Sinn, Marianne (Prof. Dr. med.), Stroth, Matthias (Dr. med.), Tamm, Ingo (Dr. med.), Trümper, Lorenz, Wilhelm, Martin (Prof. Dr. med.), Wöll, Ewald (Prim. Univ.-Prof. Dr.), and Hofheinz, Ralf-Dieter (Prof. Dr. med.)

Subjects
ddc:610
Abstract

\(\bf Background:\) 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2–1.0%. \(\bf Summary:\) Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. \(\bf Key Messages:\) (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.

Published
2020

35. Supplementary_Tablesandfigures_TAM – Supplemental material for The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study

Author

Riedl, Jakob Michael, Posch, Florian, Prager, Gerald, Eisterer, Wolfgang, Oehler, Leopold, Thamer Sliwa, Wilthoner, Klaus, Petzer, Andreas, Pichler, Petra, Hubmann, Eva, Winder, Thomas, Burgstaller, Sonja, Korger, Markus, Andel, Johannes, Greil, Richard, Hans-Joerg Neumann, Pecherstorfer, Martin, Philipp-Abbrederis, Kathrin, Djanani, Angela, Gruenberger, Birgit, Laengle, Friedrich, Wöll, Ewald, and Gerger, Armin

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_Tablesandfigures_TAM for The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study by Jakob Michael Riedl, Florian Posch, Gerald Prager, Wolfgang Eisterer, Leopold Oehler, Thamer Sliwa, Klaus Wilthoner, Andreas Petzer, Petra Pichler, Eva Hubmann, Thomas Winder, Sonja Burgstaller, Markus Korger, Johannes Andel, Richard Greil, Martin Pecherstorfer, Kathrin Philipp-Abbrederis, Angela Djanani, Birgit Gruenberger, Friedrich Laengle, Ewald Wöll and Armin Gerger in Therapeutic Advances in Medical Oncology

Published
2020
Full Text
View/download PDF

36. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

Author

Wörmann, Bernhard, Bokemeyer, Carsten, Burmeister, Thomas, Köhne, Claus-Henning, Schwab, Matthias, Arnold, Dirk, Blohmer, Jens-Uwe, Borner, Markus, Brucker, Sara, Cascorbi, Ingolf, Decker, Thomas, de Wit, Maike, Dietz, Andreas, Einsele, Hermann, Eisterer, Wolfgang, Folprecht, Gunnar, Hilbe, Wolfgang, Hoffmann, Jürgen, Knauf, Wolfgang, Kunzmann, Volker, Largiadèr, Carlo R., Lorenzen, Sylvie, Lüftner, Diana, Moehler, Markus, Nöthen, Markus M., Pox, Christian, Reinacher-Schick, Anke, Scharl, Anton, Schlegelberger, Brigitte, Seufferlein, Thomas, Sinn, Marianne, Stroth, Matthias, Tamm, Ingo, Trümper, Lorenz, Wilhelm, Martin, Wöll, Ewald, Hofheinz, Ralf-Dieter, Wörmann, Bernhard, Bokemeyer, Carsten, Burmeister, Thomas, Köhne, Claus-Henning, Schwab, Matthias, Arnold, Dirk, Blohmer, Jens-Uwe, Borner, Markus, Brucker, Sara, Cascorbi, Ingolf, Decker, Thomas, de Wit, Maike, Dietz, Andreas, Einsele, Hermann, Eisterer, Wolfgang, Folprecht, Gunnar, Hilbe, Wolfgang, Hoffmann, Jürgen, Knauf, Wolfgang, Kunzmann, Volker, Largiadèr, Carlo R., Lorenzen, Sylvie, Lüftner, Diana, Moehler, Markus, Nöthen, Markus M., Pox, Christian, Reinacher-Schick, Anke, Scharl, Anton, Schlegelberger, Brigitte, Seufferlein, Thomas, Sinn, Marianne, Stroth, Matthias, Tamm, Ingo, Trümper, Lorenz, Wilhelm, Martin, Wöll, Ewald, and Hofheinz, Ralf-Dieter

Abstract

Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2–1.0%. Summary: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring

Published
2020

37. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study

Author

Prager, Gerald W., primary, Oehler, Leopold, additional, Gerger, Armin, additional, Mlineritsch, Brigitte, additional, Andel, Johannes, additional, Petzer, Andreas, additional, Wilthoner, Klaus, additional, Sliwa, Thamer, additional, Pichler, Petra, additional, Winder, Thomas, additional, Heibl, Sonja, additional, Gruenberger, Birgit, additional, Laengle, Friedrich, additional, Hubmann, Eva, additional, Korger, Markus, additional, Pecherstorfer, Martin, additional, Djanani, Angela, additional, Neumann, Hans-Joerg, additional, Philipp-Abbrederis, Kathrin, additional, Wöll, Ewald, additional, Trondl, Robert, additional, Arnold-Schrauf, Catharina, additional, and Eisterer, Wolfgang, additional

Published
2021
Full Text
View/download PDF

39. LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases.

Author

Piringer, Gudrun, primary, Gruenberger, Thomas, additional, Kuehrer, Irene, additional, Oefner, Dietmar, additional, Kaczirek, Klaus, additional, Laengle, Friedrich, additional, Viragos-Toth, Istvan Levente, additional, Amann, Arno, additional, Eisterer, Wolfgang, additional, Fuegger, Reinhold, additional, Andel, Johannes, additional, Pichler, Angelika, additional, Stift, Judith, additional, Soelkner, Lidija, additional, Gnant, Michael, additional, and Thaler, Josef, additional

Published
2020
Full Text
View/download PDF

40. Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry

Author

Huemer, Florian, primary, Weiss, Lukas, additional, Regitnig, Peter, additional, Winder, Thomas, additional, Hartmann, Bernd, additional, Thaler, Josef, additional, Piringer, Gudrun, additional, Schmitt, Clemens A., additional, Eisterer, Wolfgang, additional, Gänzer, Hannes, additional, Wüstner, Alois, additional, Andel, Johannes, additional, Jagdt, Björn, additional, Ulmer, Hanno, additional, Greil, Richard, additional, and Wöll, Ewald, additional

Published
2020
Full Text
View/download PDF

41. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study

Author

Riedl, Jakob Michael, primary, Posch, Florian, additional, Prager, Gerald, additional, Eisterer, Wolfgang, additional, Oehler, Leopold, additional, Sliwa, Thamer, additional, Wilthoner, Klaus, additional, Petzer, Andreas, additional, Pichler, Petra, additional, Hubmann, Eva, additional, Winder, Thomas, additional, Burgstaller, Sonja, additional, Korger, Markus, additional, Andel, Johannes, additional, Greil, Richard, additional, Neumann, Hans-Joerg, additional, Pecherstorfer, Martin, additional, Philipp-Abbrederis, Kathrin, additional, Djanani, Angela, additional, Gruenberger, Birgit, additional, Laengle, Friedrich, additional, Wöll, Ewald, additional, and Gerger, Armin, additional

Published
2020
Full Text
View/download PDF

42. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

Author

Wörmann, Bernhard, primary, Bokemeyer, Carsten, additional, Burmeister, Thomas, additional, Köhne, Claus-Henning, additional, Schwab, Matthias, additional, Arnold, Dirk, additional, Blohmer, Jens-Uwe, additional, Borner, Markus, additional, Brucker, Sara, additional, Cascorbi, Ingolf, additional, Decker, Thomas, additional, de Wit, Maike, additional, Dietz, Andreas, additional, Einsele, Hermann, additional, Eisterer, Wolfgang, additional, Folprecht, Gunnar, additional, Hilbe, Wolfgang, additional, Hoffmann, Jürgen, additional, Knauf, Wolfgang, additional, Kunzmann, Volker, additional, Largiadèr, Carlo R., additional, Lorenzen, Sylvie, additional, Lüftner, Diana, additional, Moehler, Markus, additional, Nöthen, Markus M., additional, Pox, Christian, additional, Reinacher-Schick, Anke, additional, Scharl, Anton, additional, Schlegelberger, Brigitte, additional, Seufferlein, Thomas, additional, Sinn, Marianne, additional, Stroth, Matthias, additional, Tamm, Ingo, additional, Trümper, Lorenz, additional, Wilhelm, Martin, additional, Wöll, Ewald, additional, and Hofheinz, Ralf-Dieter, additional

Published
2020
Full Text
View/download PDF

48. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

Author

Desmedt, Christine, Salgado, Roberto, Fornili, Marco, Pruneri, Giancarlo, van den Eynden, Gert, Zoppoli, Gabriele, Rothé, Françoise, Buisseret, Laurence, Garaud, Soizic, Willard-Gallo, Karen, Brown, David, Bareche, Yacine, Rouas, Ghizlane, Galant, Christine, Loi, Sherene, Viale, Giuseppe, Di Leo, Angelo, Green, Andrew, Ellis, Ian, Rakha, Emad, Larsimont, Denis, Biganzoli, Elia, Sotiriou, Christos, Brodowicz, Thomas, Mir, Olivier, Wallet, Jennifer, Italiano, Antoine, Blay, Jean-Yves, Bertucci, François, Eisterer, Wolfgang, Chevreau, Christine, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Ryckewaert, Thomas, Liegl-Antzwager, Bernadette, Thery, Julien, Penel, Nicolas, Le Cesne, Axel, Le Deley, Marie-Cécile, Breast Cancer Translational Research Laboratory, Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), University of Pisa - Università di Pisa, European Institute of Oncology [Milan] (ESMO), IRCCS Ospedale Policlinico San Martino [Genoa, Italy], Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Institut des Matériaux Jean Rouxel (IMN), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Ecole Polytechnique de l'Université de Nantes (EPUN), Université de Nantes (UN)-Université de Nantes (UN)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Cliniques Universitaires Saint-Luc [Bruxelles], Division of Pathology and Laboratory Medicine, Università degli Studi di Milano = University of Milan (UNIMI)-European Institute of Oncology [Milan] (ESMO), Translational Research Unit c/o Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Academic Centre on Rare Diseases (ACoRD), University College Dublin [Dublin] (UCD), Université médicale de Vienne, Autriche, Sarcome, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Bergonié [Bordeaux], UNICANCER, Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'Oncologie Médicale [Institut Curie, Paris], Institut Curie [Paris], Département d'oncologie médicale [ICO, Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département d'oncologie médicale, Ecole de Médecine [CHRU Lille], Università degli Studi di Milano [Milano] (UNIMI)-European Institute of Oncology [Milan] (ESMO), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Etudes Médiévales de Montpellier (CEMM), and Université Paul-Valéry - Montpellier 3 (UPVM)

Subjects
0301 basic medicine, Leiomyosarcoma, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Pyridines, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Kaplan-Meier Estimate, Placebo, Placebos, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Double-Blind Method, Internal medicine, Regorafenib, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Cross-Over Studies, Proportional hazards model, business.industry, Soft tissue sarcoma, Phenylurea Compounds, Hazard ratio, Sarcoma, Middle Aged, medicine.disease, Synovial sarcoma, Progression-Free Survival, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Disease Progression, Female, business, Follow-Up Studies
Abstract

The placebo-controlled phase-2 REGOSARC trial demonstrated the efficacy of regorafenib in patients with leiomyosarcoma, synovial sarcoma and other non-adipocytic sarcoma but not in liposarcoma. Patients initially allocated to placebo were allowed to receive regorafenib after progression. We report here an updated analysis of the trial including evaluation of regorafenib activity after cross-over.From June 2013 to December 2014, 139 patients were enrolled in the non-adipocytic sarcoma cohorts. Median follow-up is now 32.4 months. Benefit of regorafenib versus placebo in terms of progression-free survival (PFS) and overall survival (OS) from randomisation was estimated by hazard ratio (HR) in Cox models. In the placebo arm, intra-patient benefit of regorafenib after cross-over was evaluated by the growth modulation index (GMI) (GMI was here, for each patient, PFS after cross-over regorafenib divided by PFS with placebo). Furthermore, the activity of delayed (after cross-over) versus early (at study entry) regorafenib was evaluated by comparing PFS after cross-over to regorafenib to PFS after randomisation in the regorafenib arm.PFS benefit of regorafenib as compared to placebo was confirmed with longer follow-up (HR = 0.50; 95% CI: 0.35-0.71; p .0001). OS was not statistically significant different (HR = 0.78; 0.54-1.12; p = .18). This finding may partially be explained by the fact that 55/68 patients who progressed on placebo (81%) received cross-over Regorafenib after progression: 59% of them had a GMI ≥ 1.3 (95% CI, 45-71%). Delayed start of regorafenib was associated with a statistically non-significant shorter PFS as compared to early treatment (HR = 1.21; 0.84-1.73; p = .30) without impact on OS.Observed PFS confirms that regorafenib warrants further clinical investigation in refractory non-adipocytic sarcomas.

Published
2018

49. Leitlinie - ICD-10 C16. : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Lordick, Florian, Eisterer, Wolfgang, Hegewisch-Becker, Susanna, Thuss-Patience, Peter, Pritzkuleit, Ron, Schweizerische Gesellschaft Für Hämatologie, Schweizerische Gesellschaft Für Medizinische Onkologie, Arnold, Dirk, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Borner, Markus M., Wöll, Ewald, Bruns, Christiane, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Faber, Gerhard, Stahl, Michael, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, and Möhler, Markus

Subjects
Medizin und Gesundheit
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results